Physician profile
Manar Michael
NPI 1407800188
$1,186.29
in general payments reported to CMS, 2019-2025
14 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $293 · 2022: $281 · 2023: $212 · 2024: $230 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $593 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $592.92 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $367.58 | 2021-2025 | Zepbound, Mounjaro |
| Abbvie INC. | $173.51 | 2021-2025 | |
| Amgen INC. | $127.44 | 2023-2025 | Prolia, Evenity, Otezla |
| Novo Nordisk INC | $109.62 | 2021-2023 | Wegovy, Saxenda, Ozempic |
| Glaxosmithkline, LLC. | $90.57 | 2021-2024 | Trelegy Ellipta |
| Nestle Healthcare Nutrition INC. | $82.62 | 2021 | |
| Dexcom, INC. | $57.61 | 2022 | |
| Ironwood Pharmaceuticals, INC | $38.58 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $35.91 | 2021-2023 | Tezspire |
| Bayer Healthcare Pharmaceuticals INC. | $34.48 | 2023-2025 | |
| Shield Therapeutics INC | $20.61 | 2024 | |
| Merck Sharp & Dohme LLC | $19.23 | 2024 | Gardasil 9, Gardasil, M-M-R II |
| Biohaven Pharmaceutical Holding Company LTD. | $15.33 | 2022 | |
| Coopersurgical, INC. | $13.20 | 2023 | Paragard T 380a |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manar Michael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.